CN112138138B - Pharmaceutical composition for treating gout and preparation method thereof - Google Patents
Pharmaceutical composition for treating gout and preparation method thereof Download PDFInfo
- Publication number
- CN112138138B CN112138138B CN202011300901.4A CN202011300901A CN112138138B CN 112138138 B CN112138138 B CN 112138138B CN 202011300901 A CN202011300901 A CN 202011300901A CN 112138138 B CN112138138 B CN 112138138B
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- pharmaceutical composition
- less
- ketoglutarate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 34
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 28
- 229930013930 alkaloid Natural products 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000003797 alkaloid derivatives Chemical class 0.000 claims abstract description 20
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 20
- 239000011591 potassium Substances 0.000 claims abstract description 20
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims abstract description 19
- 229940014041 hyaluronate Drugs 0.000 claims abstract description 19
- 241000251468 Actinopterygii Species 0.000 claims abstract description 17
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 17
- 235000019454 L-leucine Nutrition 0.000 claims abstract description 17
- 239000004395 L-leucine Substances 0.000 claims abstract description 17
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 17
- 229960003767 alanine Drugs 0.000 claims abstract description 17
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960003136 leucine Drugs 0.000 claims abstract description 17
- 229960004452 methionine Drugs 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 16
- -1 D-glucosamine ketoglutarate Chemical compound 0.000 claims abstract description 16
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims abstract description 16
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 16
- 229930064664 L-arginine Natural products 0.000 claims abstract description 16
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 16
- 229930195722 L-methionine Natural products 0.000 claims abstract description 16
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 241000195620 Euglena Species 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims abstract description 12
- 150000003384 small molecules Chemical class 0.000 claims abstract description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 6
- 235000019766 L-Lysine Nutrition 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 241001474374 Blennius Species 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 18
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 18
- 229940116269 uric acid Drugs 0.000 abstract description 18
- 206010003246 arthritis Diseases 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 208000006820 Arthralgia Diseases 0.000 abstract description 3
- 208000017667 Chronic Disease Diseases 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 201000003068 rheumatic fever Diseases 0.000 abstract description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a pharmaceutical composition for treating gout and a preparation method thereof, wherein the pharmaceutical composition comprises, by weight, 18-30 parts of euglena beta-1, 3-glucan, 15-35 parts of compound active alkaloid, 3-15 parts of deep sea fish peptide, 2-5 parts of small molecule potassium hyaluronate, 5-10 parts of D-glucosamine ketoglutarate, 3-5 parts of glutamine, 2-5 parts of L-alanine, 3-6 parts of L-arginine, 2-5 parts of L-methionine, 3-6 parts of L-lysine, 5-9 parts of L-leucine and 0.2-1 part of vitamin C, and the pharmaceutical composition is prepared in a mixing manner, and can effectively improve and treat metabolic arthritis such as gout, rheumatic arthritis, rheumatoid arthritis and other chronic diseases, repair joints, reduce joint pain, increase muscle synthesis and accelerate uric acid metabolism.
Description
Technical Field
The invention relates to a gout treatment medicine and a preparation method thereof, in particular to a medicine composition for treating gout and a preparation method thereof.
Background
Gout is a group of heterogeneous chronic metabolic diseases caused by purine metabolic disorder, and has the clinical characteristics of hyperuricemia, recurrent gouty acute arthritis, interstitial nephritis and tophus formation; severe cases are accompanied by joint deformity or uric acid urinary tract stones. The clinical characteristics of gout are as follows: hyperuricemia; recurrent episodes of gouty acute arthritis; tophus formation and deposition of tophus-like diffuse arthritis; joint deformity, and the like.
The ventilation formation process is mainly caused by excessive accumulation of uric acid, and the main reasons for the accumulation of uric acid are as follows: excessive consumption of high purine foods causes problems in purine metabolism in the body, and uric acid is not normally excreted due to too little excretion. According to the mechanism of uric acid production, it is necessary to reduce uric acid production in order to prevent gout, it is necessary to reduce purine in vivo in order to reduce uric acid production, it is necessary to reduce oxidative degradation of nucleic acid in vivo, and it is necessary to reduce purine intake, while enhancing uric acid elimination. Currently, the medicines for treating gout on the market are more medicines such as colchicine, sunflower disc alkaloid, allopurinol, probenecid and the like, the medicines treat symptoms but do not treat the root cause, a series of side effects such as serious injury to liver and kidney functions, hemolytic anemia, anaphylactic shock and the like are caused, and some plant alkaloids can neutralize uric acid, but the pain of patients is aggravated.
Disclosure of Invention
The invention aims to provide a medicinal composition for treating gout.
Another technical problem to be solved by the present invention is to provide a preparation method of the above pharmaceutical composition for treating gout.
The technical scheme adopted by the invention is as follows:
the functional components of the pharmaceutical composition for treating gout comprise 18-30 parts of euglena beta-1, 3-glucan, 15-35 parts of compound active alkaloid, 3-15 parts of deep sea fish peptide, 2-5 parts of small molecular hyaluronic acid potassium (with molecular weight smaller than 3000), 2-5 parts of D-glucosamine ketoglutarate, 3-6 parts of L-arginine, 2-5 parts of L-methionine, 3-6 parts of L-lysine, 5-9 parts of L-leucine and 0.2-1 part of vitamin C.
Preferably, the pharmaceutical composition for treating gout comprises, by weight, 26.5 parts of euglena beta-1, 3-glucan, 29.4 parts of compound active alkaloid, 7.2 parts of deep sea fish peptide, 3.5 parts of small molecule potassium hyaluronate, 8.6 parts of D-glucosamine ketoglutarate, 4.1 parts of glutamine, 3.0 parts of L-alanine, 4.2 parts of L-arginine, 3.5 parts of L-methionine, 3.5 parts of L-lysine, 6.0 parts of L-leucine and 0.5 part of vitamin C.
The medicinal composition for treating gout can be prepared into powder, capsules or granules.
The preparation method of the pharmaceutical composition for treating gout comprises the following specific steps:
(1) Weighing naked algae beta-1, 3-glucan, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate (with molecular weight less than 3000), D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C according to parts by weight;
(2) And (3) uniformly mixing the components in the step (1).
The beneficial effects of the invention are as follows:
the pharmaceutical composition for treating gout can effectively improve and treat metabolic arthritis such as gout, rheumatic arthritis, rheumatoid arthritis and other chronic diseases, repair joints, reduce joint pain, increase muscle synthesis and accelerate uric acid metabolism.
Detailed Description
To further illustrate the invention, the following examples are provided in connection with:
example 1
A pharmaceutical composition for treating gout comprises Euglena beta-1, 3-glucan, compound active alkaloid, deep sea fish peptide, small molecule potassium hyaluronate (molecular weight is less than 3000), D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the Euglena beta-1, 3-glucan is 26.5%, compound active alkaloid is 29.4%, deep sea fish peptide 7.2%, small molecule potassium hyaluronate 3.5%, D-glucosamine ketoglutarate 8.6%, glutamine 4.1%, L-alanine 3.0%, L-arginine 4.2%, L-methionine 3.5%, L-lysine 3.5%, L-leucine 6.0% and vitamin C0.5%.
The medicinal composition for treating gout is prepared into powder (5 g/bag), and the preparation method comprises the following specific steps:
(1) Weighing naked algae beta-1, 3-glucan, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate (with molecular weight less than 3000), D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C according to parts by weight;
(2) And (3) uniformly mixing the components in the step (1).
Example 2
A pharmaceutical composition for treating gout comprises Euglena beta-1, 3-glucan, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate (molecular weight is less than 3000), D-aminoglucose ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the Euglena beta-1, 3-glucan 30%, compound active alkaloid 15%, deep sea fish peptide 15%, small molecular potassium hyaluronate (molecular weight is less than 3000) 5%, D-aminoglucose ketoglutarate 5%, glutamine 5%, L-alanine 5%, L-arginine 3%, L-methionine 2%, L-lysine 3%, L-leucine 9% and vitamin C1%.
The preparation is described in example 1.
Example 3
A pharmaceutical composition for treating gout comprises Euglena beta-1, 3-glucan, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate (molecular weight is less than 3000), D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the Euglena beta-1, 3-glucan 18%, compound active alkaloid 35%, deep sea fish peptide 3%, small molecular potassium hyaluronate (molecular weight is less than 3000) 2%, D-glucosamine ketoglutarate 10%, glutamine 3%, L-alanine 2%, L-arginine 6%, L-methionine 5%, L-lysine 6%, L-leucine 5%, and vitamin C0.2%.
The preparation is described in example 1.
Example 4
A pharmaceutical composition for treating gout comprises Euglena beta-1, 3-glucan, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate (molecular weight is less than 3000), D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C, wherein the Euglena beta-1, 3-glucan 23%, compound active alkaloid 27%, deep sea fish peptide 10%, small molecular potassium hyaluronate (molecular weight is less than 3000) 4%, D-glucosamine ketoglutarate 8%, glutamine 4%, L-alanine 3%, L-arginine 5%, L-methionine 4%, L-lysine 4%, L-leucine 7% and vitamin C0.6%.
The preparation is described in example 1.
And (3) formula analysis:
(1) The euglena glucan can reduce uric acid, reduce cholesterol and strengthen resistance, the compound active alkaloid directly neutralizes uric acid, and glutamine, alanine and arginine (dilate blood vessels) and VC have the effects of protecting liver and nourishing kidney in a synergic manner; radically treating and ventilating the liver and the kidney;
(2) The small molecular nano substance is quickly absorbed, has no toxic or side effect, no hormone and no dependence;
(3) Lysine and alanine have synergistic diuretic effect, are favorable for uric acid discharge, and can synergistically inhibit severe hypertension (common ventilation with hypertension) with methionine;
(4) The small molecular potassium hyaluronate and the D-glucosamine ketoglutarate have the functions of synergistically protecting joints, softening blood vessels and the like, so that the joint pain is reduced, and the joints are repaired;
(5) Vitamin C, has effects of diminishing inflammation, relieving pain, repairing kidney, reducing urea content in vivo, and promoting absorption of other four components.
The components have synergistic effect and obvious effect of treating gout.
Experimental example 1
The pharmaceutical composition (5 g/bag) described in example 1 was administered 4 times per day, once every 6 hours, with 500-700ML of purified water per drinking. The administration is 30 days later as a treatment course. 50 cases of gout patients were tested, wherein 30 cases of young and middle-aged patients were aged 20-45 years, average age was 35.5 years, middle-aged and elderly patients were aged 46-76 years, and average age was 57.2 years. The patients are men, and all the patients accord with the diagnosis standard of gout. The uric acid level of young patients is 523+/-71.2 mu mol/L on average, and the uric acid level of middle-aged and elderly patients is 565+/-62.3 mu mol/L on average. The clinical frequency of the young patients is 3.5+/-0.6 times per year on average, and the average of the middle-aged patients and the elderly patients is 3.8+/-0.4 times per year on average.
50 patients with gout who receive treatment of the group have main lesions, 23 single arthritis cases and 34 multi-arthritis cases, the main affected joints are 46 first toe joints, 16 ankle joints, 11 other toe and plantar joints and 9 knee joints. 42 cases of drug treatment in example 1 are completely relieved, 7 cases are improved, and the clinical effective rate reaches 98.0%.
Experimental example 2
A group of 8 patients with ages of 43-61 years are selected, all men are subjected to tracking test, the uric acid values measured by venous blood of the 8 patients are all more than 550umol/L, the pharmaceutical composition (5 g/bag) described in application example 1 is taken for 4 times/day, and the pharmaceutical composition is taken once every 6 hours, and 500-700ML of purified water is drunk every time. By observation, uric acid levels decreased rapidly at day 5 and 6 patients recovered to normal values at day 30, and all recovered to normal by treatment for 60 days.
The above examples are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the scope of protection defined by the claims of the present invention without departing from the spirit of the design of the present invention.
Claims (4)
1. A pharmaceutical composition for treating gout, characterized in that: the functional components comprise, by weight, 18-30 parts of euglena beta-1, 3-glucan, 15-35 parts of compound active alkaloid, 3-15 parts of deep sea fish peptide, 2-5 parts of small molecule potassium hyaluronate, 5-5 parts of D-glucosamine ketoglutarate, 3-6 parts of glutamine, 3-6 parts of L-lysine, 5-9 parts of L-leucine and 0.2-1 part of vitamin C, wherein the molecular weight of the small molecule potassium hyaluronate is less than 3000, and the weight of the small molecule potassium hyaluronate is less than 3-35 parts of compound active alkaloid, the weight of the compound active alkaloid is less than 3-15 parts of deep sea fish peptide, the weight of the small molecule potassium hyaluronate is less than 3-5 parts of D-glucosamine ketoglutarate, the weight of glutamine is less than 3-5 parts of L-alanine, the weight of L-arginine is less than 3-6 parts of L-methionine, the weight of L-lysine is less than 3-6 parts of L-leucine and the weight of the vitamin C is less than 0.2-1 part.
2. A pharmaceutical composition for the treatment of gout according to claim 1, characterized in that: the novel compound seaweed compound preparation comprises, by weight, 26.5 parts of euglena beta-1, 3-glucan, 29.4 parts of compound active alkaloid, 7.2 parts of deep sea fish peptide, 3.5 parts of small molecule potassium hyaluronate, 8.6 parts of D-glucosamine ketoglutarate, 4.1 parts of glutamine, 3.0 parts of L-alanine, 4.2 parts of L-arginine, 3.5 parts of L-methionine, 3.5 parts of L-lysine, 6.0 parts of L-leucine and 0.5 part of vitamin C.
3. A pharmaceutical composition for the treatment of gout according to claim 1, characterized in that: the medicine composition is powder, capsule or granule.
4. A method of preparing a pharmaceutical composition for treating gout according to claim 1, characterized in that: the method comprises the following specific steps:
(1) Weighing naked algae beta-1, 3-glucan, compound active alkaloid, deep sea fish peptide, small molecular potassium hyaluronate with molecular weight less than 3000, D-glucosamine ketoglutarate, glutamine, L-alanine, L-arginine, L-methionine, L-lysine, L-leucine and vitamin C according to parts by weight;
(2) And (3) uniformly mixing the components in the step (1).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011300901.4A CN112138138B (en) | 2020-11-19 | 2020-11-19 | Pharmaceutical composition for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011300901.4A CN112138138B (en) | 2020-11-19 | 2020-11-19 | Pharmaceutical composition for treating gout and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112138138A CN112138138A (en) | 2020-12-29 |
| CN112138138B true CN112138138B (en) | 2023-05-23 |
Family
ID=73887447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011300901.4A Active CN112138138B (en) | 2020-11-19 | 2020-11-19 | Pharmaceutical composition for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112138138B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103920135A (en) * | 2014-04-23 | 2014-07-16 | 青岛昆布生物工程有限公司 | Kelp-amino composite tablet for lowering content of uric acid and preparation method thereof |
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN104645332A (en) * | 2015-03-06 | 2015-05-27 | 江苏正大清江制药有限公司 | Pharmaceutical composition for relieving and preventing arthritis |
| CN105709207A (en) * | 2016-01-29 | 2016-06-29 | 徐宝贞 | Medicine for treating gout |
| WO2017203529A1 (en) * | 2016-05-24 | 2017-11-30 | Bol Pharma Ltd. | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases |
| CN107660795A (en) * | 2017-09-01 | 2018-02-06 | 武汉龙族药号生物医药科技有限公司 | One kind prevention gout plaster taste and preparation method thereof |
| CN110946874A (en) * | 2019-12-27 | 2020-04-03 | 华熙生物科技股份有限公司 | Hyaluronic acid composition for relieving osteoarthritis |
| CN111513325A (en) * | 2020-04-29 | 2020-08-11 | 私诺(北京)健康科技有限公司 | Food for reducing uric acid |
| CN111732675A (en) * | 2020-08-18 | 2020-10-02 | 山东华熙海御生物医药有限公司 | Hyaluronic acid-glucosamine graft copolymer, preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
-
2020
- 2020-11-19 CN CN202011300901.4A patent/CN112138138B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104621432A (en) * | 2013-11-12 | 2015-05-20 | 江苏艾兰得营养品有限公司 | Glucosamine composite tablets and preparation method thereof |
| CN103920135A (en) * | 2014-04-23 | 2014-07-16 | 青岛昆布生物工程有限公司 | Kelp-amino composite tablet for lowering content of uric acid and preparation method thereof |
| CN104645332A (en) * | 2015-03-06 | 2015-05-27 | 江苏正大清江制药有限公司 | Pharmaceutical composition for relieving and preventing arthritis |
| CN105709207A (en) * | 2016-01-29 | 2016-06-29 | 徐宝贞 | Medicine for treating gout |
| WO2017203529A1 (en) * | 2016-05-24 | 2017-11-30 | Bol Pharma Ltd. | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases |
| CN107660795A (en) * | 2017-09-01 | 2018-02-06 | 武汉龙族药号生物医药科技有限公司 | One kind prevention gout plaster taste and preparation method thereof |
| CN110946874A (en) * | 2019-12-27 | 2020-04-03 | 华熙生物科技股份有限公司 | Hyaluronic acid composition for relieving osteoarthritis |
| CN111513325A (en) * | 2020-04-29 | 2020-08-11 | 私诺(北京)健康科技有限公司 | Food for reducing uric acid |
| CN111732675A (en) * | 2020-08-18 | 2020-10-02 | 山东华熙海御生物医药有限公司 | Hyaluronic acid-glucosamine graft copolymer, preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李楠等.11.2 生物碱.《有机化学第2版》.北京：中国农业大学出版社,2017, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112138138A (en) | 2020-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zulaikhah | Health benefits of tender coconut water (TCW) | |
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| US20050282772A1 (en) | New dietary supplement composition for obesity and inflammation | |
| CN106072651B (en) | It is a kind of with increasing bone density, composition of anti-inflammatory and analgesic effect and preparation method thereof | |
| CN103142655B (en) | Composite probiotics for treating podagra and preparation method thereof | |
| CN112546052A (en) | Composition containing marine oligosaccharide for preventing and treating gout | |
| CN110680906A (en) | Glucosamine bone glue peptide calcium granules | |
| CN112138138B (en) | Pharmaceutical composition for treating gout and preparation method thereof | |
| US20190000903A1 (en) | Biopolymer compositions for the treatment and prevention of liver disease | |
| CN105193837B (en) | A kind of creme and preparation method thereof of prevention and treatment joint disease | |
| CN102596214B (en) | Composition for alleviating fatty liver | |
| CN1739556A (en) | Dietotherapeutic nutrient for preventing and treating secondary gout and its prepn process | |
| CN108813636A (en) | Beneficial anahemin composition and its application | |
| WO2021115156A1 (en) | Composition containing sodium pyruvate and use thereof | |
| CN108379455B (en) | Uric acid reducing composition | |
| CN110917209A (en) | Application of selenium-containing compound or selenium nano-grade in preparation of injection or microneedle of arthritis treatment drug | |
| CN114848699A (en) | Composition with effect of reducing uric acid and preparation method and application thereof | |
| CN116585379B (en) | Traditional Chinese medicine composition, method and application for preventing and treating hyperuricemia and gout | |
| CN111228459A (en) | Composition for treating and preventing gout | |
| KR20200107809A (en) | Vitamin complex formula coated with xylitol and or Enzymatically Modified Stevia | |
| US20080095865A1 (en) | Composition and method for increasing lean muscle mass, decreasing muscle loss, increasing muscle strength and improving athletic performance | |
| CN116370574B (en) | Traditional Chinese medicine composition for preventing and treating gosling gout and preparation method thereof | |
| CN115671131B (en) | Application of acanthus trifoliatus polysaccharide in preparing medicine for treating hyperuricemia | |
| TWI679018B (en) | Composition for regulating creatinine and treating or / and preventing diseases related to metabolic syndrome | |
| CN114191499B (en) | Traditional Chinese medicine composition for relieving liver and kidney injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |